The Paris Life Sciences team advised Speedinvest on their investment in the €3 million financing of Orakl Oncology, start-up aiming to improve and accelerate pharmaceutical research in oncology.
The financing round was led by Speedinvest with additional investment from HCVC and Verve Ventures.
The Goodwin team was led by Anne-Charlotte Rivière and included Louis Taslé d’Héliand and Julie Messerig on corporate aspects, Marie Fillon and Louis de Chezelles on IP aspects.